Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (3726)	9/29/1999 2:08:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 10280

Don, The strong marketing pretty much all resides with the big pharma (and some big biotechs) who are all way beyond SEPR's means. DURA is predominantly a sales and marketing company, with respiratory as one emphasis. They have an albuterol dry powder inhaler in the pipeline, which would confuse matters. The rest of their marketing direction doesn't really fit with SEPR's pipeline. Stock is depressed. I guess I would much prefer to see a broad marketing alliance in the respiratory area with a pharma like Glaxo than a "do-it-yourself" attempt. Peter